Literature DB >> 24265358

Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography.

Leire Pérez-Latorre1, Matilde Sánchez-Conde, Diego Rincón, Pilar Miralles, Teresa Aldámiz-Echevarría, Ana Carrero, Francisco Tejerina, Cristina Díez, José María Bellón, Rafael Bañares, Juan Berenguer.   

Abstract

BACKGROUND: Hepatic venous pressure gradient (HVPG) is the best indicator of prognosis in patients with compensated cirrhosis. We compared HVPG and transient elastography (TE) for the prediction of liver-related events (LREs) in patients with hepatitis C virus (HCV)-related cirrhosis with or without human immunodeficiency virus (HIV) coinfection.
METHODS: This was a retrospective review of all consecutive patients with compensated HCV-related cirrhosis who were assessed simultaneously using TE and HVPG between January 2005 and December 2011. We used receiver operating characteristic (ROC) curves to determine the ability of TE and HVPG to predict the first LRE (liver decompensation or hepatocellular carcinoma).
RESULTS: The study included 60 patients, 36 of whom were coinfected with HIV. After a median follow-up of 42 months, 6 patients died, 8 experienced liver decompensations, and 7 were diagnosed with hepatocellular carcinoma. The area under the ROC curve (AUROC) of TE and HVPG for prediction of LREs in all patients was 0.85 (95% confidence interval [CI], .73-.97) and 0.76 (95% CI, .63-.89) (P = .13); for HIV-infected patients, the AUROC was 0.85 (95% CI, .67-1.00) and 0.81 (95% CI, .64-.97) (P = .57); and for non-HIV-infected patients, the AUROC was 0.88 (95% CI, .75-1.00) and 0.77 (95% CI, .57-.97) (P = .19). Based on the AUROC values, 2 TE cutoff points were chosen to predict the absence (<25 kPa) or presence (≥40 kPa) of LREs, thus enabling correct classification of 82% of patients.
CONCLUSIONS: Our data suggest that TE is at least as valid as HVPG for predicting LREs in patients with compensated HCV-related cirrhosis with or without concomitant HIV coinfection.

Entities:  

Keywords:  HIV infection; cirrhosis; end-stage liver disease; hepatic venous pressure gradient transient elastography; portal hypertension

Mesh:

Year:  2013        PMID: 24265358     DOI: 10.1093/cid/cit768

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  Critical comparison of elastography methods to assess chronic liver disease.

Authors:  Mireen Friedrich-Rust; Thierry Poynard; Laurent Castera
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  Advances in the management of HIV/HCV coinfection.

Authors:  Mattias Mandorfer; Philipp Schwabl; Sebastian Steiner; Thomas Reiberger; Markus Peck-Radosavljevic
Journal:  Hepatol Int       Date:  2016-01-12       Impact factor: 6.047

3.  Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection.

Authors:  Susanna Naggie; Sam Lusk; J Will Thompson; Meredith Mock; Cynthia Moylan; Joseph E Lucas; Laura Dubois; Lisa St John-Williams; M Arthur Moseley; Keyur Patel
Journal:  J Infect Dis       Date:  2020-11-13       Impact factor: 5.226

Review 4.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

Review 5.  Ending hepatitis C in the United States: the role of screening.

Authors:  Phillip O Coffin; Andrew Reynolds
Journal:  Hepat Med       Date:  2014-07-03

Review 6.  New treatments for genotype 1 chronic hepatitis C - focus on simeprevir.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Osamu Yokosuka
Journal:  Ther Clin Risk Manag       Date:  2014-05-24       Impact factor: 2.423

7.  Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C.

Authors:  Leire Pérez-Latorre; Antonio Rivero-Juárez; Víctor Hontañón; Cristina Díez; Francisca Cuenca; Maria Luz Martín-Carbonero; María L Montes; José M Bellón; Teresa Aldámiz-Echevarría; Ana Carrero; Antonio Rivero; Juan González-García; Juan Berenguer
Journal:  Open Forum Infect Dis       Date:  2016-10-03       Impact factor: 3.835

8.  Diagnostic performance of APRI and FIB-4 for confirming cirrhosis in Indonesian HIV/HCV co-infected patients.

Authors:  Evy Yunihastuti; Bramantya Wicaksana; Andrian Wiraguna; Ainum Jhariah Hidayah; Fhadilla Amelia; Veritea Natali; Alvina Widhani; Andri Sanityoso Sulaiman; Juferdy Kurniawan
Journal:  BMC Infect Dis       Date:  2020-05-25       Impact factor: 3.090

9.  Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.

Authors:  Ana Zaida Gomez-Moreno; Daniel Pineda-Tenor; Maria Angeles Jimenez-Sousa; Juan Jose Sánchez-Ruano; Tomas Artaza-Varasa; Jose Saura-Montalban; Pablo Ryan; Salvador Resino
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

Review 10.  Non-invasive tests for the prediction of primary hepatocellular carcinoma.

Authors:  Giovanni Marasco; Antonio Colecchia; Giovanni Silva; Benedetta Rossini; Leonardo Henry Eusebi; Federico Ravaioli; Elton Dajti; Luigina Vanessa Alemanni; Luigi Colecchia; Matteo Renzulli; Rita Golfieri; Davide Festi
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.